[ad_1]
Radnor, Pennsylvania, May 22, 2021 (Global News)-Kessler Topaz Meltzer & Check, LLP Law Firm announced that Kessler Topaz Meltzer & Check, LLP has targeted Emergent BioSolutions Inc. (New York Stock Exchange:Electronic Business System) (“Emergency”) represents investors who purchase or acquire emergency common stock Between April 24, 2020 and April 16, 2021(Inclusive) (“During Class”). The action (with subtitles) Roth v. Emergent BioSolutions Inc. et al., Case No. 1: 21-cv-01189-PX (“Rose Litigation”), has filed a lawsuit in the U.S. District Court of Maryland (Southern Division). Rose Action complaint please click here.
The U.S. District Court of Maryland (Southern Division) has a related class action lawsuit under trial against Emergent, and the issued notice of the lawsuit has triggered June 18, 2021, Applicable to any investor who purchases emergency common stock to seek to be appointed as the chief plaintiff representative of this category For the record Rose action constant June 18, 2021 is the deadline for the plaintiff to take the lead.
As of investor reminder: For other information or to learn how to participate in this lawsuit, please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435; Toll free (844) 887-9500; Send by email to info@ktmc.com; or access: https://www.ktmc.com/emergent-biosolutions-class-action-lawsuit?utm_source=PR&utm_medium=Link&utm_campaign=emergent.
Emergent is a professional biopharmaceutical company dedicated to the development of vaccines and antibody therapies for infectious diseases. In response to the novel coronavirus (SARS-CoV-2) that caused the COVID-19 disease (“COVID-19”) pandemic, Emergent signed a series of transactions with Johnson & Johnson (“J&J”) and AstraZeneca with a total value of 876 Ten thousand dollars to provide contract development and manufacturing organization services to produce the company’s COVID-19 vaccine candidate.
Classes began on April 24, 2020, when Emergent announced that it had reached an agreement with Johnson & Johnson to produce Johnson & Johnson’s COVID-19 vaccine candidate at its Baltimore plant. According to the agreement, Emergent will provide Johnson & Johnson with API production services and retain its large-scale production capacity. Then, on June 11, 2020, Emergent announced that it had signed another agreement to provide contract development and manufacturing services and ensure large-scale production capacity to support AstraZeneca’s COVID-19 vaccine candidate.
The truth about the emergency situation began to be disclosed after the market was closed on March 31, 2021. New York Times Published an article reporting the accidental contamination of the COVID-19 vaccine developed by Johnson & Johnson and AstraZeneca at Emergent’s Baltimore facility. This New York Times The article pointed out that in late February 2021, emergency employees at the Baltimore plant mixed the ingredients of two different COVID-19 vaccines, contaminating up to 15 million doses of Johnson & Johnson’s vaccine, and forcing regulators to postpone the plant’s production line Authorization. Also, “[f]Further shipments of Johnson & Johnson vaccines-expected to total 24 million doses next month-should come from the giant plant in Baltimore. “[t]Now, when it comes to solving quality control issues, the delivery of the hose is being questioned. “
The next morning, April 1, 2021, Associated Press According to documents obtained through the Freedom of Information Act, the report stated that the U.S. Food and Drug Administration (“FDA”) “repeatedly…cited Emergent’s problems, such as well-trained employees, broken vials, mold management and other surrounding contamination One of its facilities.” Immediately after this news, Emergent’s stock price fell sharply from the closing price of $92.91 per share on March 31, 2021 to the closing price of 80.46 per share on April 1, 2021. In the US dollar, the decline was US$12.45, or more than 13% per share.
Then, on April 19, 2021, Emergent revealed: “At the request of the FDA, Emergent agreed not to start manufacturing any new materials in its Bayview facility and to isolate existing materials manufactured in the Bayview facility until the Bayview facility is completed. [FDA’s] Check and remedy all the resulting findings. “Following this news, the price of Emergent’s common stock dropped by $9.77 per share from the closing price of $77.64 per share on April 16, 2021, a drop of more than 12%, and closed at $67.87 per share on April 19, 2021.
This Rose The lawsuit claims that during the entire class action, the defendant did not disclose: (1) Emergent’s plant in Baltimore has a history of manufacturing problems, which increases the possibility of large-scale pollution; (2) Due to these pollution risks and quality control issues, Baltimore The factory received a series of FDA citations; (3) Millions of doses of COVID-19 vaccine were discarded in an emergency after the factory’s workers deviated from manufacturing standards; (4) Due to the above reasons, the defendant regarding Emergent’s plant in Baltimore The public statement of the ability to mass produce multiple COVID-19 vaccines is essentially false and/or misleading, and/or lacks a reasonable basis.
Emerging investors may No later than June 18, 2021, Seeking to be appointed as the chief plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other consultants, or may choose not to do anything and remain absent. The lead plaintiff is the representative of the class members who represent all litigations. In order to be appointed as the lead plaintiff, the court must determine that the claim of the class member is a typical feature of the claims of other class members, and that the class member will fully represent the class. Your ability to share any recovery is not affected by the decision whether to act as the main plaintiff.
Attorney Kessler Topaz Meltzer & Check sued in state and federal courts across the country for securities fraud, breach of fiduciary duty, and other class actions that violated state and federal laws. Kessler Topaz Meltzer & Check, LLP is the driving force of corporate governance reform and has recovered billions of dollars on behalf of institutional investors and individual investors in the United States and around the world. The company represents investors, consumers and whistleblowers (private citizens who report fraud against the government and share the recovery of government funds).For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com.
contact:
Kessler Topaz Meltzer & Check, LLP
James Maro, Jr.
Adrienne Bell, Esq.
280 Prussian Road
Radnor, Pennsylvania 19087
(844) 887-9500
info@ktmc.com
[ad_2]
Source link
